Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

• Status: Active, not recruiting
• Trial end date: 2023-08-01

Summary

This is a randomised, phase II open-labelled two-arm study comparing R-GEM-P and LR-GEM in second-line treatment of Diffuse Large B-cell lymphoma. Eligible patients will be randomised 1:1 between R-GEM-P and LR-GEM.

• Phase: Phase 2

Details

• Lead Sponsor: Royal Marsden NHS Foundation Trust
• Collaborator: Celgene Corporation
• Treatments: Cisplatin; Gemcitabine; Lenalidomide; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Rituximab; Thalidomide